

5 **WHAT IS CLAIMED IS:**

1. A polypeptide having an amino acid sequence which is a fragment of the continuous collagenous region of the major triple helical domain of the $\alpha 1$ chain of type IV collagen, wherein the polypeptide is in the all D-form.
2. The polypeptide of claim 1 wherein the amino acid sequence corresponds substantially to amino acid residues 1263 through 1277 of the continuous collagenous region of the major triple helical domain of the $\alpha 1$ chain of type IV collagen.
3. The polypeptide of claim 2 having 15 amino acid residues in the D-form where appropriate.
4. The polypeptide of claim 3 having the sequence gly-val-lys-gly-asp-lys-gly-asn-pro-gly-trp-pro-gly-ala-pro.
5. The polypeptide of claim 1 further comprising a cytotoxic agent covalently bonded thereto.
6. The polypeptide of claim 1 which inhibits binding of tumor cells to type IV collagen.
7. The polypeptide of claim 1 which inhibits tumor cell invasion into basement membranes.
8. The polypeptide of claim 1 which inhibits tumor cell metastasis.
9. A peptide-conjugate comprising a polypeptide fragment of the continuous collagenous region of the major triple helical domain of the

5 $\alpha 1$ chain of type IV collagen covalently bonded to a non-peptide moiety.

10. The peptide-conjugate of claim 9 wherein the polypeptide fragment is in the all D-form.

10 11. The peptide-conjugate of claim 9 wherein the polypeptide fragment is in the all L-form.

12. The peptide-conjugate of claim 9 wherein the amino acid sequence of the polypeptide fragment corresponds substantially to amino acid residues 15
1263 through 1277 of the continuous collagenous region of the major triple helical domain of the $\alpha 1$ chain of type IV collagen.

13. The peptide-conjugate of claim 12 having 15 amino acid residues in the D-form where appropriate.

20 14. The peptide-conjugate of claim 13 having the sequence gly-val-lys-gly-asp-lys-gly-asn-pro-gly-trp-pro-gly-ala-pro.

15. The peptide-conjugate of claim 9 further comprising a cytotoxic agent covalently bonded thereto.

25 16. A method of inhibiting tumor cell binding to type IV collagen comprising contacting the tumor cell with a polypeptide of claim 1 or a peptide-conjugate of claim 9.

30 17. A method of inhibiting tumor cell invasion of a basement membrane comprising modulating the tumor cell with a polypeptide of claim 1 or a peptide-conjugate of claim 9.

35 18. A method of inhibiting tumor cell metastasis comprising modulating the

5 tumor cell with a polypeptide of claim 1 or a peptide-conjugate of claim
9.

Sub A2 19. The method of any of claims 16-18 which is carried out *in vivo*.

Add A3

and D3

A2/SJ